CARBAMAZEPINE USERS WITH CHANGED LEVELS OF OXIDATIVE STRESS BIOMARKERS
KARINE RAQUEL UHDICH KLEIBERT 1*, ALANA THAIS GISCH ANDRES 1, FERNANDA WAGNER BOZ 1, LENARA SCHALANSKI KRAUSE 1, LAIRA DUTRA 1, ANDRESSA JUNGBECK 1, ALINE SCHNEIDER 2, DAIANA ZAMBONATO 3, ANDRESSA CAROLINE DIEL 2 , IVAN RICARDO CARVALHO 1, MARIANA RODRIGUES BOTTON 4, CHRISTIANE DE FÁTIMA COLET 1
1 Regional University of the Northwest of the State of Rio Grande do Sul, Ijuí, RS, Brazil
2 Municipal Health Department of Ijuí, Ijuí, RS, Brazil
3 Hospital de Clínicas Ijuí, Ijuí, RS, Brasil
4 Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil
Download Full Article PDF
Carbamazepine (CBZ) is used for various diseases, such as mood disorders, epilepsy and chronic pain. In all of these, oxidative stress (OS) is involved in its pathophysiology; however, in Brazilian context studies, there are still no concrete data on the effect of CBZ on these parameters. This study aimed to analyse OS biomarkers among CBZ users in the Brazilian Unified Health System. A cross-sectional, analytical and quantitative analysis that included CBZ users. Data were collected via questionnaires, medical record reviews and blood samples. The OS markers analysed were catalase (CAT), superoxide dismutase (SOD), thiobarbituric acid reactive substances (TBARS) and non-protein thiols (NP-SH), which were compared to healthy controls. Higher concentrations of SOD and lower concentrations of CAT and NP-SH were observed in carbamazepine users. Higher levels of TBARS were associated with brown race and polymedication or polypharmacy. Patients who were CBZ users have changes in OS biomarkers. The study investigated the difference in OS between CBZ users with epilepsy/chronic pain and mood disorders, in addition to being one of the first in Brazil. The results contribute to the body of knowledge in the field, as the literature remains inconsistent regarding OS markers in patients receiving CBZ.
